FDA Tweaks Cancer Drug Warnings Over Hypertension Risk
The U.S. Food and Drug Administration announced Tuesday that it had amended the warning labels of Bristol-Myers Squibb Co.'s leukemia drug Sprycel to reflect the potential risk of patients developing abnormally...To view the full article, register now.
Already a subscriber? Click here to view full article